Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 14 de 14
1.
Aging Cell ; 22(4): e13782, 2023 04.
Article En | MEDLINE | ID: mdl-36734200

Cardiomyopathy is a progressive disease of the myocardium leading to impaired contractility. Genotoxic cancer therapies are known to be potent drivers of cardiomyopathy, whereas causes of spontaneous disease remain unclear. To test the hypothesis that endogenous genotoxic stress contributes to cardiomyopathy, we deleted the DNA repair gene Ercc1 specifically in striated muscle using a floxed allele of Ercc1 and mice expressing Cre under control of the muscle-specific creatinine kinase (Ckmm) promoter or depleted systemically (Ercc1-/D mice). Ckmm-Cre+/- ;Ercc1-/fl mice expired suddenly of heart disease by 7 months of age. As young adults, the hearts of Ckmm-Cre+/- ;Ercc1-/fl mice were structurally and functionally normal, but by 6-months-of-age, there was significant ventricular dilation, wall thinning, interstitial fibrosis, and systolic dysfunction indicative of dilated cardiomyopathy. Cardiac tissue from the tissue-specific or systemic model showed increased apoptosis and cardiac myocytes from Ckmm-Cre+/- ;Ercc1-/fl mice were hypersensitive to genotoxins, resulting in apoptosis. p53 levels and target gene expression, including several antioxidants, were increased in cardiac tissue from Ckmm-Cre+/- ;Ercc1-/fl and Ercc1-/D mice. Despite this, cardiac tissue from older mutant mice showed evidence of increased oxidative stress. Genetic or pharmacologic inhibition of p53 attenuated apoptosis and improved disease markers. Similarly, overexpression of mitochondrial-targeted catalase improved disease markers. Together, these data support the conclusion that DNA damage produced endogenously can drive cardiac disease and does so mechanistically via chronic activation of p53 and increased oxidative stress, driving cardiac myocyte apoptosis, dilated cardiomyopathy, and sudden death.


Cardiomyopathy, Dilated , Myocytes, Cardiac , Mice , Animals , Myocytes, Cardiac/metabolism , Cardiomyopathy, Dilated/genetics , Cardiomyopathy, Dilated/metabolism , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism , Myocardium/metabolism , DNA Repair
3.
Nature ; 594(7861): 100-105, 2021 06.
Article En | MEDLINE | ID: mdl-33981041

Ageing of the immune system, or immunosenescence, contributes to the morbidity and mortality of the elderly1,2. To define the contribution of immune system ageing to organism ageing, here we selectively deleted Ercc1, which encodes a crucial DNA repair protein3,4, in mouse haematopoietic cells to increase the burden of endogenous DNA damage and thereby senescence5-7 in the immune system only. We show that Vav-iCre+/-;Ercc1-/fl mice were healthy into adulthood, then displayed premature onset of immunosenescence characterized by attrition and senescence of specific immune cell populations and impaired immune function, similar to changes that occur during ageing in wild-type mice8-10. Notably, non-lymphoid organs also showed increased senescence and damage, which suggests that senescent, aged immune cells can promote systemic ageing. The transplantation of splenocytes from Vav-iCre+/-;Ercc1-/fl or aged wild-type mice into young mice induced senescence in trans, whereas the transplantation of young immune cells attenuated senescence. The treatment of Vav-iCre+/-;Ercc1-/fl mice with rapamycin reduced markers of senescence in immune cells and improved immune function11,12. These data demonstrate that an aged, senescent immune system has a causal role in driving systemic ageing and therefore represents a key therapeutic target to extend healthy ageing.


Aging/immunology , Aging/physiology , Immune System/immunology , Immune System/physiology , Immunosenescence/immunology , Immunosenescence/physiology , Organ Specificity/immunology , Organ Specificity/physiology , Aging/drug effects , Aging/pathology , Animals , DNA Damage/immunology , DNA Damage/physiology , DNA Repair/immunology , DNA Repair/physiology , DNA-Binding Proteins/genetics , Endonucleases/genetics , Female , Healthy Aging/immunology , Healthy Aging/physiology , Homeostasis/immunology , Homeostasis/physiology , Immune System/drug effects , Immunosenescence/drug effects , Male , Mice , Organ Specificity/drug effects , Rejuvenation , Sirolimus/pharmacology , Spleen/cytology , Spleen/transplantation
4.
Cancer Cell ; 39(2): 193-208.e10, 2021 02 08.
Article En | MEDLINE | ID: mdl-33357452

Adoptive therapy using chimeric antigen receptor-modified T cells (CAR-T cells) is effective in hematologic but not epithelial malignancies, which cause the greatest mortality. In breast and lung cancer patients, CAR-T cells targeting the tumor-associated antigen receptor tyrosine kinase-like orphan receptor 1 (ROR1) infiltrate tumors poorly and become dysfunctional. To test strategies for enhancing efficacy, we adapted the KrasLSL-G12D/+;p53f/f autochthonous model of lung adenocarcinoma to express the CAR target ROR1. Murine ROR1 CAR-T cells transferred after lymphodepletion with cyclophosphamide (Cy) transiently control tumor growth but infiltrate tumors poorly and lose function, similar to what is seen in patients. Adding oxaliplatin (Ox) to the lymphodepletion regimen activates tumor macrophages to express T-cell-recruiting chemokines, resulting in improved CAR-T cell infiltration, remodeling of the tumor microenvironment, and increased tumor sensitivity to anti-PD-L1. Combination therapy with Ox/Cy and anti-PD-L1 synergistically improves CAR-T cell-mediated tumor control and survival, providing a strategy to improve CAR-T cell efficacy in the clinic.


Immune Checkpoint Inhibitors/immunology , Lung Neoplasms/immunology , Receptors, Antigen, T-Cell/immunology , Receptors, Chimeric Antigen/immunology , T-Lymphocytes/immunology , Animals , Antigens, Neoplasm/immunology , Cell Line , Cell Line, Tumor , HEK293 Cells , Humans , Immunotherapy, Adoptive/methods , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Receptor Tyrosine Kinase-like Orphan Receptors/immunology , Tumor Microenvironment/immunology
5.
Geroscience ; 41(4): 455-465, 2019 08.
Article En | MEDLINE | ID: mdl-31468322

An understanding of early-onset mechanisms underlying age-related changes can be obtained by evaluating changes that precede frailty and end of life using histological characterization of age-related lesions. Histopathology-based information as a component of aging studies in mice can complement and add context to molecular, cellular, and physiologic data, but there is a lack of information regarding scoring criteria and lesion grading guidelines. This report describes the validation of a grading system, designated as the geropathology grading platform (GGP), which generated a composite lesion score (CLS) for comparison of histological lesion scores in tissues from aging mice. To assess reproducibility of the scoring system, multiple veterinary pathologists independently scored the same slides from the heart, lung, liver, and kidney from two different strains (C57BL/6 and CB6F1) of male mice at 8, 16, 24, and 32 months of age. There was moderate to high agreement between pathologists, particularly when agreement within a 1-point range was considered. CLS for all organs was significantly higher in older versus younger mice, suggesting that the GGP was reliable for detecting age-related pathology in mice. The overall results suggest that the GGP guidelines reliably distinguish between younger and older mice and may therefore be accurate in distinguishing between experimental groups of mice with more, or less, age-related pathology.


Aging/pathology , Animals , Kidney/pathology , Liver/pathology , Lung/pathology , Mice, Inbred C57BL , Models, Animal , Myocardium/pathology
6.
Sci Transl Med ; 11(503)2019 07 31.
Article En | MEDLINE | ID: mdl-31366581

The androgen receptor (AR) is a driver of cellular differentiation and prostate cancer development. An extensive body of work has linked these normal and aberrant cellular processes to mRNA transcription; however, the extent to which AR regulates posttranscriptional gene regulation remains unknown. Here, we demonstrate that AR uses the translation machinery to shape the cellular proteome. We show that AR is a negative regulator of protein synthesis and identify an unexpected relationship between AR and the process of translation initiation in vivo. This is mediated through direct transcriptional control of the translation inhibitor 4EBP1. We demonstrate that lowering AR abundance increases the assembly of the eIF4F translation initiation complex, which drives enhanced tumor cell proliferation. Furthermore, we uncover a network of pro-proliferation mRNAs characterized by a guanine-rich cis-regulatory element that is particularly sensitive to eIF4F hyperactivity. Using both genetic and pharmacologic methods, we demonstrate that dissociation of the eIF4F complex reverses the proliferation program, resulting in decreased tumor growth and improved survival in preclinical models. Our findings reveal a druggable nexus that functionally links the processes of mRNA transcription and translation initiation in an emerging class of lethal AR-deficient prostate cancer.


Prostatic Neoplasms/metabolism , Receptors, Androgen/metabolism , Regulon/physiology , Adaptor Proteins, Signal Transducing/genetics , Adaptor Proteins, Signal Transducing/metabolism , Animals , Cell Cycle Proteins/genetics , Cell Cycle Proteins/metabolism , Cell Proliferation/genetics , Cell Proliferation/physiology , Humans , In Vitro Techniques , Introns/genetics , Male , Mice , Prostatic Neoplasms/genetics , Receptors, Androgen/genetics , Regulon/genetics
7.
Cancer Discov ; 8(11): 1422-1437, 2018 11.
Article En | MEDLINE | ID: mdl-30181244

CREBBP, encoding an acetyltransferase, is among the most frequently mutated genes in small cell lung cancer (SCLC), a deadly neuroendocrine tumor type. We report acceleration of SCLC upon Crebbp inactivation in an autochthonous mouse model. Extending these observations beyond the lung, broad Crebbp deletion in mouse neuroendocrine cells cooperated with Rb1/Trp53 loss to promote neuroendocrine thyroid and pituitary carcinomas. Gene expression analyses showed that Crebbp loss results in reduced expression of tight junction and cell adhesion genes, including Cdh1, across neuroendocrine tumor types, whereas suppression of Cdh1 promoted transformation in SCLC. CDH1 and other adhesion genes exhibited reduced histone acetylation with Crebbp inactivation. Treatment with the histone deacetylase (HDAC) inhibitor Pracinostat increased histone acetylation and restored CDH1 expression. In addition, a subset of Rb1/Trp53/Crebbp-deficient SCLC exhibited exceptional responses to Pracinostat in vivo Thus, CREBBP acts as a potent tumor suppressor in SCLC, and inactivation of CREBBP enhances responses to a targeted therapy.Significance: Our findings demonstrate that CREBBP loss in SCLC reduces histone acetylation and transcription of cellular adhesion genes, while driving tumorigenesis. These effects can be partially restored by HDAC inhibition, which exhibited enhanced effectiveness in Crebbp-deleted tumors. These data provide a rationale for selectively treating CREBBP-mutant SCLC with HDAC inhibitors. Cancer Discov; 8(11); 1422-37. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1333.


CREB-Binding Protein/physiology , Drug Resistance, Neoplasm , Histone Deacetylases/chemistry , Lung Neoplasms/pathology , Retinoblastoma Protein/physiology , Small Cell Lung Carcinoma/pathology , Tumor Suppressor Protein p53/physiology , Acetylation , Animals , Cell Movement , Cell Proliferation , Cell Transformation, Neoplastic , Epithelial-Mesenchymal Transition , Gene Expression Regulation, Neoplastic , Histone Deacetylase Inhibitors/pharmacology , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/metabolism , Mice , Mice, Knockout , Mutation , Small Cell Lung Carcinoma/drug therapy , Small Cell Lung Carcinoma/metabolism , Tumor Cells, Cultured
8.
Biol Blood Marrow Transplant ; 24(1): 50-54, 2018 01.
Article En | MEDLINE | ID: mdl-28958896

In murine model systems inducible costimulator (ICOS) signaling has been implicated in the formation of chronic graft-versus-host disease (GVHD). Previously, we showed that chronic GVHD can be reproducibly produced in the dog hematopoietic cell transplantation (HCT) model and that ICOS expression is upregulated on T cells in dogs with chronic GVHD. The goal of the present study was to determine whether administration of a short course of anti-canine ICOS mAb could alter the rapid and progressive course of chronic GVHD. Five dogs underwent HCT from dog leukocyte antigen mismatched unrelated donors after total body irradiation. Postgrafting immunosuppression consisted of methotrexate (days 1, 3, 6, and 11) and cyclosporine (days -1 through 78). Anti-ICOS mAb (3 injections, 72 hours apart) was administered upon diagnosis of GVHD. One dog failed to respond to anti-ICOS mAb therapy and succumbed to chronic GVHD in a time course similar to control untreated dogs. Overall, anti-ICOS-treated dogs experienced a significant prolongation in survival from the time of diagnosis of chronic GVHD compared with control dogs. Within the limitations of the number of study dogs we suggest that a short course of anti-ICOS mAb may be useful in the treatment of chronic canine GVHD.


Antibodies, Monoclonal/therapeutic use , Graft vs Host Disease/therapy , Inducible T-Cell Co-Stimulator Protein/immunology , Animals , Antibodies, Monoclonal/pharmacology , Antigens, Surface , Disease Models, Animal , Dogs , Graft vs Host Disease/mortality , Hematopoietic Stem Cell Transplantation , Immunosuppression Therapy/methods , Survival Rate , Treatment Outcome
9.
J Clin Invest ; 127(6): 2176-2191, 2017 Jun 01.
Article En | MEDLINE | ID: mdl-28436934

Therapies using T cells that are programmed to express chimeric antigen receptors (CAR T cells) consistently produce positive results in patients with hematologic malignancies. However, CAR T cell treatments are less effective in solid tumors for several reasons. First, lymphocytes do not efficiently target CAR T cells; second, solid tumors create an immunosuppressive microenvironment that inactivates T cell responses; and third, solid cancers are typified by phenotypic diversity and thus include cells that do not express proteins targeted by the engineered receptors, enabling the formation of escape variants that elude CAR T cell targeting. Here, we have tested implantable biopolymer devices that deliver CAR T cells directly to the surfaces of solid tumors, thereby exposing them to high concentrations of immune cells for a substantial time period. In immunocompetent orthotopic mouse models of pancreatic cancer and melanoma, we found that CAR T cells can migrate from biopolymer scaffolds and eradicate tumors more effectively than does systemic delivery of the same cells. We have also demonstrated that codelivery of stimulator of IFN genes (STING) agonists stimulates immune responses to eliminate tumor cells that are not recognized by the adoptively transferred lymphocytes. Thus, these devices may improve the effectiveness of CAR T cell therapy in solid tumors and help protect against the emergence of escape variants.


Biopolymers/administration & dosage , Carcinoma, Pancreatic Ductal/therapy , Melanoma, Experimental/therapy , Pancreatic Neoplasms/therapy , Adoptive Transfer , Animals , Antigen-Presenting Cells/physiology , Antineoplastic Agents/administration & dosage , Carcinoma, Pancreatic Ductal/immunology , Cell Line, Tumor , Cyclic GMP/administration & dosage , Cyclic GMP/analogs & derivatives , Drug Carriers/administration & dosage , Female , Implants, Experimental , Melanoma, Experimental/immunology , Membrane Proteins/agonists , Mice, Inbred C57BL , Mice, Transgenic , Neoplasm Transplantation , Pancreatic Neoplasms/immunology , T-Lymphocytes/physiology
10.
Nat Nanotechnol ; 12(8): 813-820, 2017 08.
Article En | MEDLINE | ID: mdl-28416815

An emerging approach for treating cancer involves programming patient-derived T cells with genes encoding disease-specific chimeric antigen receptors (CARs), so that they can combat tumour cells once they are reinfused. Although trials of this therapy have produced impressive results, the in vitro methods they require to generate large numbers of tumour-specific T cells are too elaborate for widespread application to treat cancer patients. Here, we describe a method to quickly program circulating T cells with tumour-recognizing capabilities, thus avoiding these complications. Specifically, we demonstrate that DNA-carrying nanoparticles can efficiently introduce leukaemia-targeting CAR genes into T-cell nuclei, thereby bringing about long-term disease remission. These polymer nanoparticles are easy to manufacture in a stable form, which simplifies storage and reduces cost. Our technology may therefore provide a practical, broadly applicable treatment that can generate anti-tumour immunity 'on demand' for oncologists in a variety of settings.


DNA/chemistry , Drug Carriers , Gene Transfer Techniques , Immunity, Cellular/drug effects , Leukemia/therapy , Nanoparticles/chemistry , Receptors, Chimeric Antigen , T-Lymphocytes/immunology , Animals , Cell Line, Tumor , Drug Carriers/chemistry , Drug Carriers/pharmacology , Immunity, Cellular/genetics , Leukemia/genetics , Leukemia/immunology , Leukemia/pathology , Mice , Receptors, Chimeric Antigen/genetics , Receptors, Chimeric Antigen/immunology
11.
J Gerontol A Biol Sci Med Sci ; 72(6): 760-762, 2017 Jun 01.
Article En | MEDLINE | ID: mdl-28329081

Testing drugs for anti-aging effects has historically been conducted in mouse life-span studies, but are costly and time consuming, and more importantly, difficult to recapitulate in humans. In addition, life-span studies in mice are not well suited to testing drug combinations that target multiple factors involved in aging. Additional paradigms for testing therapeutics aimed at slowing aging are needed. A new paradigm, designated as the Geropathology Grading Platform (GGP), is based on a standardized set of guidelines developed to detect the presence or absence of low-impact histopathological lesions and to determine the level of severity of high-impact lesions in organs from aged mice. The GGP generates a numerical score for each age-related lesion in an organ, summed for total lesions, and averaged over multiple mice to obtain a composite lesion score (CLS). Preliminary studies show that the platform generates CLSs that increase with the age of mice in an organ-dependent manner. The CLSs are sensitive enough to detect changes elicited by interventions that extend mouse life span, and thus help validate the GGP as a novel tool to measure biological aging. While currently optimized for mice, the GGP could be adapted to any preclinical animal model.


Aging/drug effects , Drug Evaluation, Preclinical/methods , Advisory Committees , Aged , Aging/pathology , Animals , Biomedical Research , Humans , Pathology/methods , Translational Research, Biomedical
12.
J Zoo Wildl Med ; 44(4): 1102-6, 2013 Dec.
Article En | MEDLINE | ID: mdl-24450079

An adult female, wild North American porcupine (Erethizon dorsatum) presented with bilateral cataracts and naso-ocular discharge. A pregnancy was identified by radiography with a near-full-term fetus, which was delivered stillborn 4 wk later with hard, developed quills. At that time, a repeated examination and further imaging, including computed tomography, demonstrated a uterine mass that was identified as a choriocarcinoma following ovariohysterectomy. Additionally, numerous exfoliated quills were discovered throughout the abdomen, most of which were removed during the surgical procedure. Ultimately, development of peritonitis despite medical care led to the porcupine's death. Necropsy confirmed a wide migration of the quills with extensive serosal adhesions and granulomas affecting liver, lungs, urinary bladder, kidneys, and gastrointestinal tract.


Fetal Death/veterinary , Porcupines , Pregnancy Complications/veterinary , Animals , Choriocarcinoma/pathology , Choriocarcinoma/surgery , Choriocarcinoma/veterinary , Female , Pregnancy , Uterine Neoplasms/pathology , Uterine Neoplasms/surgery , Uterine Neoplasms/veterinary
13.
Influenza Other Respir Viruses ; 5(4): 268-75, 2011 Jul.
Article En | MEDLINE | ID: mdl-21651737

BACKGROUND: European starlings (Sturnus vulgaris) are common, widely distributed birds in North America that frequently come into contact with agricultural operations. However, starlings have been one of the neglected land-based wild bird species for influenza surveillance. OBJECTIVES: To study the potential role of starlings in the ecology and epidemiology of influenza virus. METHODS: We collected 328 digestive and 156 tracheal samples from starlings in Ohio in years 2007 (July) to 2008 (August) and screened for the presence of influenza virus by real-time RT-PCR, standard RT-PCR and virus isolation using embryonated chicken eggs. In addition, we conducted an experimental infection study to evaluate the replication and induction of antibody response by two low pathogenic avian influenza (AI) viruses in starlings. RESULTS: Although virus isolation was negative, we confirmed 21 influenza positive digestive and tracheal samples by real-time and standard RT-PCR tests. Phylogenetic analysis revealed that five NS genes recovered from Starlings belonged to NS subtype A and were most similar to the NS genes from a wild aquatic bird origin isolate from Ohio. Experimental infection studies using two low pathogenic AI strains showed that starlings could be infected, shed virus, and seroconvert. CONCLUSIONS: This study shows that starlings can carry influenza virus that is genetically similar to wild aquatic bird origin strains and may serve as a carrier of influenza virus to domestic animals.


Genes, Viral , Influenza A virus/isolation & purification , Influenza in Birds/virology , RNA, Viral/isolation & purification , Starlings/virology , Animals , Chick Embryo , Cluster Analysis , Digestive System/virology , Influenza A virus/genetics , Molecular Sequence Data , Ohio , Phylogeny , RNA, Viral/genetics , Reverse Transcriptase Polymerase Chain Reaction , Sequence Analysis, DNA , Trachea/virology , Viral Nonstructural Proteins/genetics , Virus Cultivation
14.
Virol J ; 7: 5, 2010 Jan 12.
Article En | MEDLINE | ID: mdl-20067630

We undertook one of the most detailed studies on the distribution of alpha2,3 sialic acid (SA)-galactose (gal) (avian type) and alpha2,6SA-gal (human type) receptors on different tissues of chickens, ducks and turkeys of varying age groups. On the tracheal epithelium, all 3 bird species expressed strong positive staining (80-90%) for alpha2,3SA-gal receptors in the 3 different age groups. In addition, a lesser amount of alpha2,6SA-gal receptors (30-90%) were observed with slight differences in distribution with age and species. The epithelium of the small and large intestine of turkeys and ducks showed negligible staining for alpha2,6SA-gal receptors whereas the large intestine consistently showed 40-70% positive staining for alpha2,3SA-gal receptors. In contrast, a greater amount of staining for alpha2,3SA-gal (50-80%) and alpha2,6SA-gal (20-50%) receptors were observed along the epithelium of small and large intestine of chickens. Kidney and esophagus sections from the 3 bird species also expressed both avian and human type receptors. In other tissues examined, brain, breast muscles, bursa, spleen, cecal tonsils and oviduct, human type receptors were absent. Though different viral and receptor components may play roles in successful viral replication and transmission, understanding the receptor types and distribution in different tissues of domestic birds might be good initial tool to understand host factors that promote successful influenza viral infection.


Cell Membrane/chemistry , Galactose/analogs & derivatives , Galactose/analysis , Genetic Variation , Influenza A virus/physiology , Receptors, Virus/analysis , Viral Tropism , Age Factors , Animal Structures/chemistry , Animals , Chickens , Ducks , Humans , Intestinal Mucosa/chemistry , Respiratory Mucosa/chemistry , Turkeys
...